$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny

$alny Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000117867021000028 Filed on October 28, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$258.5M	$187.6M	$125.9M
YoY Change	58.07%	49.09%	79.63%
Cost Of Revenue	$37.66M	$28.09M	$20.83M
YoY Change	63.76%	34.88%	299.5%
Gross Profit	$220.9M	$159.5M	$105.0M
YoY Change	57.2%	51.91%	61.96%
Gross Profit Margin	85.43%	85.03%	83.45%
Selling, General & Admin	$186.4M	$142.1M	$167.5M
YoY Change	12.08%	-15.16%	39.15%
% of Gross Profit	84.39%	89.05%	159.46%
Research & Development	$229.1M	$194.6M	$161.8M
YoY Change	35.93%	20.27%	0.61%
% of Gross Profit	103.7%	121.96%	154.04%
Depreciation & Amortization	$11.38M	$11.79M	$8.600M
YoY Change	9.38%	37.05%	-183.5%
% of Gross Profit	5.15%	7.39%	8.19%
Operating Expenses	$415.4M	$336.6M	$329.3M
YoY Change	24.08%	2.25%	17.11%
Operating Profit	-$194.6M	-$181.7M	-$225.2M
YoY Change	0.13%	-19.33%	4.11%
Interest Expense	-$60.68M	$40.27M	$28.73M
YoY Change	121.45%	40.18%
% of Operating Profit
Other Income/Expense, Net	-$5.064M	-$22.56M	-$27.25M
YoY Change	-76.98%	-17.22%	-469.78%
Pretax Income	-$260.3M	-$204.2M	-$252.5M
YoY Change	6.86%	-19.1%	20.83%
Income Tax	-$1.842M	$278.0K	$839.0K
% Of Pretax Income
Net Earnings	-$258.5M	-$204.5M	-$253.3M
YoY Change	6.13%	-19.26%	21.46%
Net Earnings / Revenue	-99.97%	-109.0%	-201.26%
Basic Earnings Per Share		-$1.72	-$2.18
Diluted Earnings Per Share	-$2.158M	-$1.72	-$2.18
COMMON SHARES
Basic Shares Outstanding	119.6M shares	119.1M shares	116.0M shares
Diluted Shares Outstanding		119.1M shares	116.0M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.369B	$2.255B	$1.777B
YoY Change	29.45%	26.94%	3.23%
Cash & Equivalents	$820.0M	$1.094B	$496.7M
Short-Term Investments	$1.549B	$1.161B	$1.280B
Other Short-Term Assets	$88.08M	$108.5M	$74.80M
YoY Change	40.25%	45.1%	1.77%
Inventory	$86.36M	$97.90M	$66.94M
Prepaid Expenses
Receivables	$198.6M	$141.1M	$79.12M
Other Receivables	$73.27M	$23.58M	$518.3M
Total Short-Term Assets	$2.809B	$2.675B	$2.555B
YoY Change	7.41%	4.72%	34.65%
LONG-TERM ASSETS
Property, Plant & Equipment	$502.0M	$484.9M	$444.7M
YoY Change	7.94%	9.05%	12.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$60.20M	$35.27M	$37.93M
YoY Change	33.65%	-7.03%	293.81%
Total Long-Term Assets	$834.7M	$797.0M	$752.6M
YoY Change	5.36%	5.9%	16.8%
TOTAL ASSETS
Total Short-Term Assets	$2.809B	$2.675B	$2.555B
Total Long-Term Assets	$834.7M	$797.0M	$752.6M
Total Assets	$3.643B	$3.472B	$3.307B
YoY Change	6.93%	4.99%	30.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$73.43M	$40.05M	$27.87M
YoY Change	41.3%	43.69%	-29.24%
Accrued Expenses	$395.2M	$388.6M	$295.3M
YoY Change	11.03%	31.6%	65.92%
Deferred Revenue	$149.5M	$115.0M	$114.6M
YoY Change	17.51%	0.39%	6.75%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$695.7M	$610.7M	$480.2M
YoY Change	18.87%	27.16%	36.1%
LONG-TERM LIABILITIES
Long-Term Debt	$675.7M	$433.8M	$0.00
YoY Change	253.21%
Other Long-Term Liabilities	$98.96M	$76.45M	$16.34M
YoY Change	161.06%	367.84%	80.84%
Total Long-Term Liabilities	$98.96M	$76.45M	$16.34M
YoY Change	161.06%	367.84%	80.84%
TOTAL LIABILITIES
Total Short-Term Liabilities	$695.7M	$610.7M	$480.2M
Total Long-Term Liabilities	$98.96M	$76.45M	$16.34M
Total Liabilities	$3.055B	$2.716B	$2.092B
YoY Change	27.78%	29.83%	123.88%
SHAREHOLDERS EQUITY
Retained Earnings	-$5.438B	-$5.180B	-$4.342B
YoY Change	18.6%	19.3%	25.82%
Common Stock	$6.060B	$5.970B	$5.594B
YoY Change	7.34%	6.72%	9.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$588.2M	$755.9M	$1.215B
YoY Change
Total Liabilities & Shareholders Equity	$3.643B	$3.472B	$3.307B
YoY Change	6.93%	4.99%	30.12%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	-$258.5M	-$204.5M	-$253.3M
YoY Change	6.13%	-19.26%	21.46%
Depreciation, Depletion And Amortization	$11.38M	$11.79M	$8.600M
YoY Change	9.38%	37.05%	-183.5%
Cash From Operating Activities	-$150.1M	-$134.0M	-$110.3M
YoY Change	21.87%	21.52%	-39.59%
INVESTING ACTIVITIES
Capital Expenditures	-$21.89M	-$26.06M	-$12.40M
YoY Change	0.86%	110.18%	-65.65%
Acquisitions
YoY Change
Other Investing Activities	-$391.5M	-$62.21M	$2.400M
YoY Change	413.13%	-2692.04%	-90.77%
Cash From Investing Activities	-$413.4M	-$88.27M	-$10.10M
YoY Change	322.27%	773.97%	1.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	292.3M	573.8M	34.10M
YoY Change	34.08%	1582.81%	-264.73%
NET CHANGE
Cash From Operating Activities	-150.1M	-134.0M	-110.3M
Cash From Investing Activities	-413.4M	-88.27M	-10.10M
Cash From Financing Activities	292.3M	573.8M	34.10M
Net Change In Cash	-271.3M	351.5M	-86.30M
YoY Change	8650.16%	-507.34%	-59.54%
FREE CASH FLOW
Cash From Operating Activities	-$150.1M	-$134.0M	-$110.3M
Capital Expenditures	-$21.89M	-$26.06M	-$12.40M
Free Cash Flow	-$128.3M	-$108.0M	-$97.90M
YoY Change	26.36%	10.29%	-33.17%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001178670
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36407
	dei	Entity Registrant Name EntityRegistrantName	ALNYLAM PHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0602661
	dei	Entity Address Address Line1 EntityAddressAddressLine1	675 West Kendall Street,
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Henri A. Termeer Square
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
	dei	City Area Code CityAreaCode	617
	dei	Local Phone Number LocalPhoneNumber	551-8200
	dei	Local Phone Number LocalPhoneNumber	551-8200
	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
	dei	Trading Symbol TradingSymbol	ALNY
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	119601177	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1093991000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	496580000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1161324000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1333182000	USD
CY2021Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	72550000	USD
CY2020Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	44633000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	141064000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	102413000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	97899000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	75202000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	108534000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	62767000	USD
CY2021Q3	alny	Royalties Receivable Current RoyaltiesReceivableCurrent	0	USD
CY2020Q4	alny	Royalties Receivable Current RoyaltiesReceivableCurrent	500000000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	2675362000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	2614777000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	484941000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	465029000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	235853000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	241485000	USD
CY2021Q3	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	40890000	USD
CY2020Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	40725000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	35267000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	45045000	USD
CY2021Q3	us-gaap	Assets Assets	3472313000	USD
CY2020Q4	us-gaap	Assets Assets	3407061000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	40048000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	51966000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	388576000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	355909000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	40612000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	36872000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	115044000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	127207000	USD
CY2021Q3	alny	Royalty Liability Current RoyaltyLiabilityCurrent	26376000	USD
CY2020Q4	alny	Royalty Liability Current RoyaltyLiabilityCurrent	13316000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	610656000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	585270000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	286030000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	293039000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	177123000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	225094000	USD
CY2021Q3	us-gaap	Long Term Debt LongTermDebt	433799000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	191278000	USD
CY2021Q3	alny	Royalty Liability Noncurrent RoyaltyLiabilityNoncurrent	1132362000	USD
CY2020Q4	alny	Royalty Liability Noncurrent RoyaltyLiabilityNoncurrent	1058225000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	76450000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	37908000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	2716420000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	2390814000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	119480000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	119480000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	116427000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	116427000	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	1195000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1164000	USD
CY2021Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	5968661000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	5644074000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-34230000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-43622000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5179733000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4585369000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	755893000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1016247000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3472313000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3407061000	USD
CY2021Q3	us-gaap	Revenues Revenues	187633000	USD
CY2020Q3	us-gaap	Revenues Revenues	125853000	USD
	us-gaap	Revenues Revenues	585752000	USD
	us-gaap	Revenues Revenues	329291000	USD
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	28091000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	20826000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	81370000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	52393000	USD
CY2021Q3	alny	Cost Of Collaboration Manufacturing And Royalties CostOfCollaborationManufacturingAndRoyalties	4572000	USD
CY2020Q3	alny	Cost Of Collaboration Manufacturing And Royalties CostOfCollaborationManufacturingAndRoyalties	971000	USD
	alny	Cost Of Collaboration Manufacturing And Royalties CostOfCollaborationManufacturingAndRoyalties	21110000	USD
	alny	Cost Of Collaboration Manufacturing And Royalties CostOfCollaborationManufacturingAndRoyalties	2635000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	194572000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	161783000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	563106000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	486350000	USD
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	142075000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	167472000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	434257000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	422129000	USD
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	369310000	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	351052000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	1099843000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	963507000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-181677000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-225199000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-514091000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-634216000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	40274000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	28731000	USD
	us-gaap	Interest Expense InterestExpense	106205000	USD
	us-gaap	Interest Expense InterestExpense	55979000	USD
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	225000	USD
CY2020Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2072000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1084000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	10717000	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	17490000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-594000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	27370000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	67477000	USD
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-22559000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-27253000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-77751000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	22215000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-204236000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-252452000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-591842000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-612001000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	278000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	839000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2522000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2740000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-204514000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-253291000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-594364000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-614741000	USD
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.72
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.72
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.18
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.18
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.37
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	119141000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	119141000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115986000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115986000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	118005000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	118005000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	114554000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	114554000	shares
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-204514000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-253291000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-594364000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-614741000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-64000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1481000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-312000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	768000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1857000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-2576000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	9530000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1665000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-58000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-76000	USD
	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-174000	USD
	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-222000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1851000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3981000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	9392000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-675000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-202663000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-257272000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-584972000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-615416000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1016247000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	47034000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	0	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	56295000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6905000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-200291000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	926190000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	75449000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	7718000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32928000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	636000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-189559000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	853362000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	71499000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	0	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	33695000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1851000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-204514000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	755893000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1438692000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	54221000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	0	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	34578000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	4459000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-182221000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	1349729000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	91873000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	5301000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	99498000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	33707000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1153000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-179229000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	1399726000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	32212000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	129000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	0	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	40228000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3981000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-253291000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	1215023000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-594364000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-614741000	USD
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	36192000	USD
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	24386000	USD
	alny	Amortization And Interest Accretion Related To Operating Leases AmortizationAndInterestAccretionRelatedToOperatingLeases	32051000	USD
	alny	Amortization And Interest Accretion Related To Operating Leases AmortizationAndInterestAccretionRelatedToOperatingLeases	29169000	USD
	alny	Non Cash Interest Expense On Sale Of Future Royalties NonCashInterestExpenseOnSaleOfFutureRoyalties	87197000	USD
	alny	Non Cash Interest Expense On Sale Of Future Royalties NonCashInterestExpenseOnSaleOfFutureRoyalties	55979000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	121135000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	105597000	USD
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	61273000	USD
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	66626000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	35222000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	1628000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	42350000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	35070000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	15655000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	26962000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	48765000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-6455000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	48738000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	75564000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-60094000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-15924000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	29586000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	31272000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-491552000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-491817000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	54486000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	48693000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	973146000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1469451000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1172100000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1190714000	USD
	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	26140000	USD
	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	9900000	USD
	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	25975000	USD
	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	0	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	4198000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	300000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	140105000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-337630000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	201227000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	181459000	USD
	alny	Proceeds From Sale Of Royalties Interest ProceedsFromSaleOfRoyaltiesInterest	500000000	USD
	alny	Proceeds From Sale Of Royalties Interest ProceedsFromSaleOfRoyaltiesInterest	500000000	USD
	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	16100000	USD
	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	4200000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	99498000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	250000000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	alny	Payments For Transaction Costs Related To Sale Of Future Royalties And Debt PaymentsForTransactionCostsRelatedToSaleOfFutureRoyaltiesAndDebt	12500000	USD
	alny	Payments For Transaction Costs Related To Sale Of Future Royalties And Debt PaymentsForTransactionCostsRelatedToSaleOfFutureRoyaltiesAndDebt	8128000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	597412000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	954827000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	777029000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-5968000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1946000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-50472000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	499046000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	549628000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1096458000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	499156000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9414000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	7048000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	7876000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	34363000	USD
	alny	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	0	USD
	alny	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	500000000	USD
	us-gaap	Nature Of Operations NatureOfOperations	NATURE OF BUSINESS<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, we, our or us) commenced operations on June 14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on ribonucleic acid interference, or RNAi. We are committed to the advancement of our company strategy of building a multi-product, global, commercial biopharmaceutical company with a deep and sustainable clinical pipeline of RNAi therapeutics for future growth and a robust, organic research engine for sustainable innovation and great potential for patient impact. Since inception, we have focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic alliances with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic partners. We have devoted substantially all of our efforts to business planning, research, development, manufacturing and early commercial efforts, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In early 2021, we launched our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy, which focuses on our planned transition to a top five biotech company, as measured by market capitalization, by the end of 2025. With </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we aim to deliver transformative rare and prevalent disease medicines for patients around the world through sustainable innovation, delivering exceptional financial performance and driving profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September 30, 2021, we have four products that have received marketing approval, including one partnered product, and six late-stage investigational programs advancing towards potential commercialization. We currently generate worldwide product revenues from three commercialized products, ONPATTRO, GIVLAARI and OXLUMO, primarily in the U.S., Europe and Japan.</span></div>
CY2021Q3	alny	Number Of Marketed Products NumberOfMarketedProducts	4	product
CY2021Q3	alny	Number Of Partnered Products NumberOfPartneredProducts	1	product
CY2021Q3	alny	Number Of Clinical Programs In Late Stages NumberOfClinicalProgramsInLateStages	6	program
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Reclassification</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain prior period amounts in the condensed consolidated financial statements have been reclassified to conform to the current period presentation.</span></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In our condensed consolidated financial statements, we use estimates and assumptions related to our inventory valuation and related reserves, liability related to the sale of future royalties, development derivative liability, income taxes, revenue recognition, research and development expenses, and stock-based compensation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, the supply of our products and product candidates, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and variants thereof, and the actions taken to contain or treat it or vaccinate against it, as well as the economic impact on local, regional, national and international customers and markets. </span></div>We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.
CY2021Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	23584000	USD
CY2020Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	33542000	USD
CY2021Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	76452000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	120021000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	12700000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	65200000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	19200000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	50700000	USD
CY2021Q3	alny	Increase Decrease In Research And Development Expense IncreaseDecreaseInResearchAndDevelopmentExpense	-3300000	USD
	alny	Increase Decrease In Research And Development Expense IncreaseDecreaseInResearchAndDevelopmentExpense	-12700000	USD
CY2020Q3	alny	Increase Decrease In Research And Development Expense IncreaseDecreaseInResearchAndDevelopmentExpense	-3200000	USD
	alny	Increase Decrease In Research And Development Expense IncreaseDecreaseInResearchAndDevelopmentExpense	-8400000	USD
	alny	Royalty Liability Payments RoyaltyLiabilityPayments	152000	USD
	alny	Impairment Of Marketable Debt Securities ImpairmentOfMarketableDebtSecurities	0	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1171288000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	146000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	110000	USD
CY2020Q3	alny	Impairment Of Marketable Debt Securities ImpairmentOfMarketableDebtSecurities	0	USD
	alny	Impairment Of Marketable Debt Securities ImpairmentOfMarketableDebtSecurities	0	USD
CY2021Q3	alny	Impairment Of Marketable Debt Securities ImpairmentOfMarketableDebtSecurities	0	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1171324000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1352834000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	463000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	115000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1353182000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1161324000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1333182000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	10000000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	20000000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1171324000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1353182000	USD
CY2021Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	65158000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	63460000	USD
CY2021Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	33124000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	16149000	USD
CY2021Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	12667000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	12693000	USD
CY2021Q3	alny	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	110949000	USD
CY2020Q4	alny	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	92302000	USD
CY2021Q3	alny	Capitalized Inventory CapitalizedInventory	7100000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1093991000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	496704000	USD
CY2021Q3	us-gaap	Restricted Cash RestrictedCash	2467000	USD
CY2020Q3	us-gaap	Restricted Cash RestrictedCash	2452000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1096458000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	499156000	USD
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	9311000	USD
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-81000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	9392000	USD
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-1658000	USD
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-983000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-675000	USD
CY2021Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.15
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	37264000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	121135000	USD
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	33367000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	105597000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12961000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13001000	shares

Files In Submission

Name	View Source	Status
0001178670-21-000028-index-headers.html	Edgar Link	pending
0001178670-21-000028-index.html	Edgar Link	pending
0001178670-21-000028.txt	Edgar Link	pending
0001178670-21-000028-xbrl.zip	Edgar Link	pending
alny-20210930.htm	Edgar Link	pending
alny-20210930.xsd	Edgar Link	pending
alny-20210930_cal.xml	Edgar Link	unprocessable
alny-20210930_def.xml	Edgar Link	unprocessable
alny-20210930_g1.jpg	Edgar Link	pending
alny-20210930_htm.xml	Edgar Link	completed
alny-20210930_lab.xml	Edgar Link	unprocessable
alny-20210930_pre.xml	Edgar Link	unprocessable
alny2021q310-qex101.htm	Edgar Link	pending
alny2021q310-qex311.htm	Edgar Link	pending
alny2021q310-qex312.htm	Edgar Link	pending
alny2021q310-qex321.htm	Edgar Link	pending
alny2021q310-qex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny

2021 Q4 Form 10-Q Financial Statement

#000117867021000028 Filed on October 28, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALNY ALNYLAM PHARMACEUTICALS, INC. Stock $alny

2021 Q4 Form 10-Q Financial Statement

#000117867021000028 Filed on October 28, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny